Loading data for SABS — first visit, this takes a few seconds.
SAB Biotherapeutics Inc. (SABS)
NasdaqCM: SABS
· Real-Time Price · USD
3.88
+0.00 (0.00%)
At close: Aug 27, 2026, 2:18 PM
The price, the headline numbers and the latest news, in one place.
SAB Biotherapeutics Inc. (SABS) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 2.78 |
| Market Cap | 353.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.79M |
| 0.53 | |
| 0.24 | |
| 16.17 | |
| -4.07 | |
| P/B (ttm) | 1.51 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 5.04 |
| Volume | 23,475 |
| Avg. Volume (20D) | 672,026 |
| Open | 3.86 |
| Previous Close | 3.88 |
| Day's Range | 3.83 - 3.90 |
| 52-Week Range | 1.85 - 5.15 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founde...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 86
Stock Exchange NasdaqCM
Ticker Symbol SABS
Website https://www.sab.bio
Financial Performance
In 2025, SAB Biotherapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were 13.27M, a decrease of -138.92%.
Financial StatementsEarnings Surprise
SAB Biotherapeutics has released their quarterly earnings on Aug 6, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.28 misses estimates by 0.00, with 50.00% YoY growth.
SAB Biotherapeutics Inc. is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2